The Epidemiology Group studies the patterns, causes and effects of neurocognitive disorders, in particular dementia, in elderly populations in Australia and internationally.

The Genomics & Epigenomics Group has grown out of our interest in gaining a greater insight into the genomic, epigenomic and transcriptomic factors contributing to healthy ageing, exceptional longevity, age-related decline and disease.

The Neuroimaging Laboratory (NiL) was established in 1991 in response to a need for the assessment of brain images, in order to improve our understanding of the brain in health and disease.

The Neuropsychiatry Group is a collaborative group composed of staff from CHeBA and the Neuropsychiatric Institute (NPI). This tertiary referral unit specialises in the diagnosis and treatment of cognitive and psychiatric disorders associated with medical and neurological illnesses.

The Neuropsychology Group investigates cognitive changes associated with normal ageing and late-life disorders of cognition, to better understand the characteristic profiles associated with different neuropathological conditions including Alzheimer’s disease and cerebrovascular disease.

The Molecular Biomarkers Group has a focus on identifying blood biomarkers and understanding mechanisms of neurodegenerative diseases of ageing, particularly the dementias, using techniques such as proteomics, metabolomics and mass spectrometry

Exploring how social and structural factors shape brain health, with a focus on equity in cognitive ageing and dementia prevention.